Amorfix closes first tranche of private financing

Amorfix Life Sciences (TSX:AMF) has closed the first tranche of a non-brokered private placement, totaling 3,012,532 units at a price of 22.5 cents each for gross proceeds of $677,820. Each unit consists of one common share of Amorfix and one warrant, with each warrant entitling the holder to purchase an additional share at a price [...]

Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Amorfix seeking partner for Alzheimer’s test

Amorfix Life Sciences (TSX:AMF) has updated its Alzheimer’s disease diagnostic program, saying that it has achieved 85% specificity and sensitivity with its EP-AD CSF diagnostic test and is now actively seeking a development partner to bring this new asset to the market as quickly as possible. Unlike tests that measure changes in the levels of [...]

Amorfix and reMYND in A4 pact for AD

Amorfix Life Sciences (TSX:AMF) has signed a partnership agreement with reMYND NV of Belgium to offer the Amorfix A4 amyloid testing service to reMYND’s contract research clients.  ”This partnership is an important first step to accessing new clients as we build our Alzheimer’s disease services business,” Vigen Nazarian, VP of strategic alliances for Amorfix, said [...]

Amorfix in ALS vaccine license with Pan-Provinical

Amorfix Life Sciences (TSX:AMF) has granted Pan-Provincial Vaccine Enterprise of Saskatoon exclusive worldwide rights to Amorfix’s lead amyotrophic lateral sclerosis vaccines, which have shown efficacy in animal models of ALS. Under the accord, Pan will develop vaccine formulations, finish preclinical studies for regulatory approvals and conduct clinical testing of the vaccines at their cost.  Upon [...]

Theratechnologies CEO retires; Amorfix’s steps down

Yves Rosconi, CEO and President of Theratechnologies (TSX:TH), has informed the board of his decision to retire on Dec. 31, 2010, saying he deferred his decision until the company’s lead tesamorelin product was in the final stages of the FDA approval process. A strategic committee of the board will immediately begin the formal search for [...]

Amorfix suspends blood testing for vCJD

Amorfix Life Sciences (TSX:AMF) has suspended development to commercialize its blood test for variant Creutzfeldt-Jakob disease (vCJD) after two new recently developed versions of the test did not yield positive results. “Although we were able to achieve unprecedented sensitivity with brain prions diluted into blood, we have been unable to detect blood prions with the [...]

Amorfix and Epitomics to develop monoclonal antibodies

Amorfix Life Sciences (TSX:AMF) and Epitomics of California and China have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes on misfolded proteins with its ProMIS platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies. [...]

Amorfix has Alzheimer’s disease blood screening breakthrough

Amorfix Life Sciences (TSX:AMF) has detected Alzheimer’s disease-associated aggregated Beta-amyloid (ABeta), the hallmark of the disease, in the blood of transgenic mice, including both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD. “This milestone achievement represents the first time that [...]

Amorfix names Gundel as VP of R&D

Amorfix Life Sciences (TSX:AMF) has appointed 25-year drug development veteran Dr. Robert Gundel as vice president of research and development. “Robert’s extensive record of new product advancement will be a great asset as we continue to discover, develop and commercialize novel diagnostic and therapeutic products based on our Epitope Protection and ProMIS technology platforms,” Dr. [...]

Next Page »